Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Pulmonology Reports
Erschienen in: Current Pulmonology Reports 1/2020

22.02.2020 | Lung Transplant (R Bag, Section Editor)

Human Cytomegalovirus Prophylaxis and Treatment in Lung Transplantation in the Current Era

verfasst von: Kathleen M. Mullane

Erschienen in: Current Pulmonology Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Human cytomegalovirus (HCMV) is an important cause of morbidity and mortality in solid organ transplantation with lung transplant recipients being at highest risk. This article sumarizes recent findings in the pathophysiology of HCMV, especially its effects in lung transplant recipients; the current and new modalities for treatment and prevention of infection; and the latest guidelines for prevention and management of HCMV in lung transplant recipients.

Recent Findings

Recent findings include moves towards standardization for monitoring and treating HCMV and approval of a new agent, letermovir, for prevention of HCMV reactivation in hematopoietic cell transplant recipients now in clinical trials for solid organ transplant recipients, and updates on the late stage development of maribavir. The newest innovations include promising vaccine candidates as well as adoptive cell-mediated immunity through the use of virus-specific cytotoxic T cells. Finally, assays evaluating HCMV immune function to aid in the evaluation of individual patient’s ability to have a cell-mediated immune response to CMV are being developed.

Summary

In the past 15 years major advances in diagnosis, prevention, management and risk evaluation in patients with HCMV have occurred, and research continues, which will impact outcomes in the transplant population.
Literatur
1.
Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86–102.PubMedPubMedCentral
2.
Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034.PubMed
3.
Nolan N, Halai UA, Regunath H, Smith L, Rojas-Moreno C, Salzer W. Primary cytomegalovirus infection in immunocompetent adults in the United States - a case series. IDCases. 2017;10:123–6.PubMedPubMedCentral
4.
Britt WJ, Prichard MN. New therapies for human cytomegalovirus infections. Antivir Res. 2018;159:153–74.PubMed
5.
Piret J, Boivin G. Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance. Antivir Res. 2019;163:91–105.PubMed
6.
Sinzger C, Digel M, Jahn G. Cytomegalovirus cell tropism. Curr Top Microbiol Immunol. 2008;325:63–83.
7.
Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008;5:47.PubMedPubMedCentral
8.
Cunha BA, Chawla K. Fever of unknown origin (FUO): CMV infectious mononucleosis or lymphoma? Eur J Clin Microbiol Infect Dis. 2018;37(7):1373–6.
9.
Orlikowski D, Porcher R, Sivadon-Tardy V, Quincampoix JC, Raphael JC, Durand MC, et al. Guillain-Barre syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis. 2011;52(7):837–44.PubMed
10.
Cockbain BC, Mora Peris B, Abbara A, So CW, Cooke G. Disseminated CMV infection and HLH in a patient with well-controlled HIV and ulcerative colitis. BMJ Case Rep. 2019;12(2).PubMedPubMedCentral
11.
Waqas QA, Abdullah HMA, Khan UI, Oliver T. Human cytomegalovirus pneumonia in an immunocompetent patient: a very uncommon but treatable condition. BMJ Case Rep. 2019;12(8).PubMedPubMedCentral
12.
Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–31.PubMed
13.
Westall GP, Cristiano Y, Levvey BJ, Whitford H, Paraskeva MA, Paul E, et al. A randomized study of quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation. Transplantation. 2019;103(5):1005–13.PubMed
14.
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87–91.
15.
Navarro D, San-Juan R, Manuel O, Gimenez E, Fernandez-Ruiz M, Hirsch HH, et al. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: an ESGICH survey. Transpl Infect Dis. 2017;19(6).
16.
Beam E, Lesnick T, Kremers W, Kennedy CC, Razonable RR. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis. Clin Transpl. 2016;30(3):270–8.PubMed
17.
Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817–24.PubMed
18.
Meesing A, Razonable RR. Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation. Expert Rev Clin Pharmacol. 2018;11(8):773–88.PubMed
19.
Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 2013;26(4):703–27.PubMedPubMedCentral
20.
Razonable RR, Humar A, Practice AST IDCOP. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):93–106.PubMed
21.
Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152(12):761–9.PubMed
22.
Kaminski H, Fishman JA. The cell biology of cytomegalovirus: implications for transplantation. Am J Transplant. 2016;16(8):2254–69.PubMed
23.
Roman A, Manito N, Campistol JM, Cuervas-Mons V, Almenar L, Arias M, et al. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev. (Orlando). 2014;28(2):84–91.PubMed
24.
Shweish O, Dronavalli G. Indications for lung transplant referral and listing. J Thorac Dis. 2019;11(Suppl 14):S1708–S20.PubMedPubMedCentral
25.
Crawford TC, Grimm JC, Magruder JT, Ha J, Sciortino CM, Kim BS, et al. Lung transplant mortality is improving in recipients with a lung allocation score in the upper quartile. Ann Thorac Surg. 2017;103(5):1607–13.PubMed
26.
Elde S, Huddleston S, Jackson S, Kelly R, Shumway S, Loor G. Tailored approach to surgical exposure reduces surgical site complications after bilateral lung transplantation. Surg Infect. 2017;18(8):929–35.PubMed
27.
Adegunsoye A, Strek ME, Garrity E, Guzy R, Bag R. Comprehensive care of the lung transplant patient. Chest. 2017;152(1):150–64.PubMed
28.
Chang A, Musk M, Lavender M, Wrobel J, Yaw MC, Lawrence S, et al. Cytomegalovirus viremia in lung transplantation during and after prophylaxis. Transpl Infect Dis. 2019;21(3):e13069.PubMed
29.
Solidoro P, Patrucco F, Libertucci D, Verri G, Sidoti F, Curtoni A, et al. Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis. Ther Adv Respir Dis. 2019;13:1753466619878555.
30.
Khanna R. Immune monitoring of infectious complications in transplant patients: an important step towards improved clinical management. J Clin Microbiol. 2018;56(4).
31.
Mabilangan C, Preiksaitis J, Cervera C, University of Alberta Cardiothoracic Transplant G. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients. Transpl Infect Dis. 2018;20(5):e12964.PubMed
32.
Mian M, Natori Y, Ferreira V, Selzner N, Husain S, Singer L, et al. Evaluation of a novel global immunity assay to predict infection in organ transplant recipients. Clin Infect Dis. 2018;66(9):1392–7.
33.
Monforte V, Sintes H, Lopez-Gallo C, Delgado M, Santos F, Zurbano F, et al. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: a prospective, observational, multicenter study. Transpl Infect Dis. 2017;19(3).
34.
Khurana MP, Lodding IP, Mocroft A, Sorensen SS, Perch M, Rasmussen A, et al. Risk factors for failure of primary (val) ganciclovir prophylaxis against cytomegalovirus infection and disease in solid organ transplant recipients. Open Forum Infect Dis. 2019;6(6):ofz215.
35.
Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010;65(12):2628–40.
36.
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420–6.PubMedCentral
37.
Humar A, Michaels M. Monitoring AIWGoID. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262–74.PubMed
38.
Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288–97.
39.
McSharry BP, Avdic S, Slobedman B. Human cytomegalovirus encoded homologs of cytokines, chemokines and their receptors: roles in immunomodulation. Viruses. 2012;4(11):2448–70.PubMedPubMedCentral
40.
Charpak-Amikam Y, Kubsch T, Seidel E, Oiknine-Djian E, Cavaletto N, Yamin R, et al. Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20. Sci Rep. 2017;7(1):8661.PubMedPubMedCentral
41.
Schwartz M, Stern-Ginossar N. The Transcriptome of Latent Human Cytomegalovirus. J Virol. 2019;93(11).
42.
Dupont L, Reeves MB. Cytomegalovirus latency and reactivation: recent insights into an age old problem. Rev Med Virol. 2016;26(2):75–89.PubMed
43.
Jackson SE, Sedikides GX, Okecha G, Wills MR. Generation, maintenance and tissue distribution of T cell responses to human cytomegalovirus in lytic and latent infection. Med Microbiol Immunol. 2019;208(3–4):375–89.PubMedPubMedCentral
44.
Krishna BA, Poole EL, Jackson SE, Smit MJ, Wills MR, Sinclair JH. Latency-associated expression of human cytomegalovirus US28 attenuates cell signaling pathways to maintain latent infection. MBio. 2017;8(6).
45.
Wills MR, Poole E, Lau B, Krishna B, Sinclair JH. The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies? Cell Mol Immunol. 2015;12(2):128–38.PubMed
46.
Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol. 2006;87(Pt 7):1763–79.PubMed
47.
Jergovic M, Contreras NA, Nikolich-Zugich J. Impact of CMV upon immune aging: facts and fiction. Med Microbiol Immunol. 2019;208(3–4):263–9.PubMedPubMedCentral
48.
Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, et al. Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Front Immunol. 2019;10:2247.PubMedPubMedCentral
49.
Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6(2):e16103.PubMedPubMedCentral
50.
Dey M, Ahmed AU, Lesniak MS. Cytomegalovirus and glioma: putting the cart before the horse. J Neurol Neurosurg Psychiatry. 2015;86(2):191–9.PubMed
51.
Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro-Oncology. 2012;14(3):246–55.PubMedPubMedCentral
52.
Savva GM, Pachnio A, Kaul B, Morgan K, Huppert FA, Brayne C, et al. Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell. 2013;12(3):381–7.PubMed
53.
Pawelec G, Derhovanessian E. Role of CMV in immune senescence. Virus Res. 2011;157(2):175–9.PubMed
54.
Costa C, Saldan A, Sinesi F, Sidoti F, Balloco C, Simeone S, et al. The lack of cytomegalovirus-specific cellular immune response may contribute to the onset of organ infection and disease in lung transplant recipients. Int J Immunopathol Pharmacol. 2012;25(4):1003–9.PubMed
55.
Snyder LD, Chan C, Kwon D, Yi JS, Martissa JA, Copeland CA, et al. Polyfunctional T cell signatures to predict protection from cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 2016;193(1):78–85.PubMedPubMedCentral
56.
Abate D, Fiscon M, Saldan A, Cofano S, Mengoli C, Sgarabotto D, et al. Human cytomegalovirus-specific T cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J Clin Microbiol. 2012;50(6):1974–80.PubMedPubMedCentral
57.
Costa C, Astegiano S, Terlizzi ME, Sidoti F, Curtoni A, Solidoro P, et al. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients. Transplant Proc. 2011;43(4):1159–61.PubMed
58.
Snyder LD, Medinas R, Chan C, Sparks S, Davis WA, Palmer SM, et al. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant. 2011;11(3):553–60.PubMedPubMedCentral
59.
Egli A, Binet I, Binggeli S, Jager C, Dumoulin A, Schaub S, et al. Cytomegalovirus-specific T cell responses and viral replication in kidney transplant recipients. J Transl Med. 2008;6:29.PubMedPubMedCentral
60.
De Gracia-Guindo MDC, Ruiz-Fuentes MDC, Galindo-Sacristan P, Osorio-Moratalla JM, Ruiz-Fuentes N, Rodriguez Granger J, et al. Cytomegalovirus infection monitoring based on interferon gamma release assay in kidney transplantation. Transplant Proc. 2018;50(2):578–80.PubMed
61.
Tarasewicz A, Debska-Slizien A, Rutkowski B. Clinical utility of QuantiFERON-cytomegalovirus test in management of kidney transplant recipients. Transplant Proc. 2016;48(5):1650–3.PubMed
62.
Abate D, Saldan A, Mengoli C, Fiscon M, Silvestre C, Fallico L, et al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol. 2013;51(8):2501–7.PubMedPubMedCentral
63.
Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am J Transplant. 2008;8(7):1486–97.PubMed
64.
Nebbia G, Mattes FM, Smith C, Hainsworth E, Kopycinski J, Burroughs A, et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant. 2008;8(12):2590–9.PubMed
65.
Martin-Gandul C, Mueller NJ, Pascual M, Manuel O. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015;15(12):3024–40.PubMed
66.
Weseslindtner L, Gorzer I, Roedl K, Kung E, Jaksch P, Klepetko W, et al. Intrapulmonary human cytomegalovirus replication in lung transplant recipients is associated with a rise of CCL-18 and CCL-20 chemokine levels. Transplantation. 2017;101(1):197–203.PubMed
67.
Weseslindtner L, Gorzer I, Kung E, Roedl K, Jaksch P, Klepetko W, et al. High CXCL-16 levels correlate with symptomatic disease in lung transplant recipients with human cytomegalovirus replication in the allograft. Am J Transplant. 2014;14(10):2406–11.PubMed
68.
Weseslindtner L, Nachbagauer R, Kundi M, Jaksch P, Kerschner H, Simon B, et al. Human cytomegalovirus infection in lung transplant recipients triggers a CXCL-10 response. Am J Transplant. 2011;11(3):542–52.PubMed
69.
Tsicopoulos A, Chang Y, Ait Yahia S, de Nadai P, Chenivesse C. Role of CCL18 in asthma and lung immunity. Clin Exp Allergy. 2013;43(7):716–22.PubMed
70.
Mah AY, Cooper MA. Metabolic regulation of natural killer cell IFN-gamma production. Crit Rev Immunol. 2016;36(2):131–47.PubMedPubMedCentral
71.
Biolatti M, Gugliesi F, Dell’Oste V, Landolfo S. Modulation of the innate immune response by human cytomegalovirus. Infect Genet Evol. 2018;64:105–14.PubMed
72.
Kwakkel-van Erp JM, van de Graaf EA, Paantjens AW, van Ginkel WG, Schellekens J, van Kessel DA, et al. The killer immunoglobulin-like receptor (KIR) group A haplotype is associated with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2008;27(9):995–1001.PubMed
73.
Calabrese DR, Lanier LL, Greenland JR. Natural killer cells in lung transplantation. Thorax. 2019;74(4):397–404.PubMed
74.
Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, et al. The trafficking of natural killer cells. Immunol Rev. 2007;220:169–82.PubMedPubMedCentral
75.
76.
Bayard C, Lepetitcorps H, Roux A, Larsen M, Fastenackels S, Salle V, et al. Coordinated expansion of both memory T cells and NK cells in response to CMV infection in humans. Eur J Immunol. 2016;46(5):1168–79.PubMed
77.
Calabrese DR, Chong T, Wang A, Singer JP, Gottschall M, Hays SR, et al. NKG2C natural killer cells in bronchoalveolar lavage are associated with cytomegalovirus viremia and poor outcomes in lung allograft recipients. Transplantation. 2019;103(3):493–501.PubMedPubMedCentral
78.
Caliendo AM, St George K, Allega J, Bullotta AC, Gilbane L, Rinaldo CR. Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J Clin Microbiol. 2002;40(5):1581–6.PubMedPubMedCentral
79.
Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol. 2008;41(3):237–41.PubMed
80.
Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK, et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9(2):258–68.PubMed
81.
Cardenoso L, Pinsky BA, Lautenschlager I, Aslam S, Cobb B, Vilchez RA, et al. CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients. J Clin Virol. 2013;56(2):108–12.PubMed
82.
Flexman J, Kay I, Fonte R, Herrmann R, Gabbay E, Palladino S. Differences between the quantitative antigenemia assay and the cobas amplicor monitor quantitative PCR assay for detecting CMV viraemia in bone marrow and solid organ transplant patients. J Med Virol. 2001;64(3):275–82.PubMed
83.
Preiksaitis JK, Hayden RT, Tong Y, Pang XL, Fryer JF, Heath AB, et al. Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis. 2016;63(5):583–9.PubMed
84.
Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis. 2012;54(12):1793–7.PubMedPubMedCentral
85.
Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis. 2002;185(12):1723–8.PubMed
86.
Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355(9220):2032–6.PubMed
87.
Hirsch HH, Lautenschlager I, Pinsky BA, Cardenoso L, Aslam S, Cobb B, et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis. 2013;56(3):367–73.PubMed
88.
Hayden RT, Sun Y, Tang L, Procop GW, Hillyard DR, Pinsky BA, et al. Progress in quantitative viral load testing: variability and impact of the WHO quantitative international standards. J Clin Microbiol. 2017;55(2):423–30.PubMedPubMedCentral
89.
Naegele K, Lautenschlager I, Gosert R, Loginov R, Bir K, Helantera I, et al. Cytomegalovirus sequence variability, amplicon length, and DNase-sensitive non-encapsidated genomes are obstacles to standardization and commutability of plasma viral load results. J Clin Virol. 2018;104:39–47.PubMed
90.
Freyer J HA, Anderson R, Minor P. Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus for nucleic acid amplification-based assays: WHO/BS/10.2138. 2010.
91.
Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation. Drugs. 2018;78(11):1085–103.PubMed
92.
Chou S, Ercolani RJ, Sahoo MK, Lefterova MI, Strasfeld LM, Pinsky BA. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother. 2014;58(8):4697–702.PubMedPubMedCentral
93.
Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection. Transplantation. 2016;100(10):e74–80.PubMedPubMedCentral
94.
Bruminhent J, Rotjanapan P, Watcharananan SP. Epidemiology and outcome of ganciclovir-resistant cytomegalovirus infection after solid organ transplantation: a single transplant center experience in Thailand. Transplant Proc. 2017;49(5):1048–52.PubMed
95.
Chemaly RF, Hill JA, Voigt S, Peggs KS. In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review. Antivir Res. 2019;163:50–8.PubMed
96.
Boeckh M, Murphy WJ, Peggs KS. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant. 2015;21(1):24–9.PubMed
97.
Lea AP, Bryson HM. Cidofovir. Drugs. 1996;52(2):225–30 discussion 31.PubMed
98.
Chou S. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antivir Res. 2017;148:1–4.PubMed
99.
Deleenheer B, Spriet I, Maertens J. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation. Expert Opin Drug Metab Toxicol. 2018;14(12):1197–207.PubMed
100.
Marshall WL, McCrea JB, Macha S, Menzel K, Liu F, van Schanke A, et al. Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects. J Clin Pharmacol. 2018;58(7):897–904.PubMed
101.
Kropeit D, McCormick D, Erb-Zohar K, Moiseev VS, Kobalava ZD, Stobernack HP, et al. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment. Br J Clin Pharmacol. 2017;83(12):2678–86.PubMedPubMedCentral
102.
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–44.PubMed
103.
Grossi P, Mohacsi P, Szabolcs Z, Potena L. Cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation. 2016;100(Suppl 3):S1–4.PubMedPubMedCentral
104.
Krmpotic A, Podlech J, Reddehase MJ, Britt WJ, Jonjic S. Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades’ resume. Med Microbiol Immunol. 2019;208(3–4):415–29.PubMedPubMedCentral
105.
Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7(9):2106–13.PubMed
106.
Rea F, Potena L, Yonan N, Wagner F, Calabrese F. Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation. Transplantation. 2016;100(Suppl 3):S19–26.PubMedPubMedCentral
107.
Germer M, Herbener P, Schuttrumpf J. Functional properties of human cytomegalovirus hyperimmunoglobulin and standard immunoglobulin preparations. Ann Transplant. 2016;21:558–64.PubMed
108.
Miescher SM, Huber TM, Kuhne M, Lieby P, Snydman DR, Vensak JL, et al. In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins. Vox Sang. 2015;109(1):71–8.PubMed
109.
Schampera MS, Schweinzer K, Abele H, Kagan KO, Klein R, Rettig I, et al. Comparison of cytomegalovirus (CMV)-specific neutralization capacity of hyperimmunoglobulin (HIG) versus standard intravenous immunoglobulin (IVIG) preparations: impact of CMV IgG normalization. J Clin Virol. 2017;90:40–5.PubMed
110.
Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation. 2010;90(6):672–6.PubMed
111.
Le Page AK, Jager MM, Kotton CN, Simoons-Smit A, Rawlinson WD. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation. 2013;95(12):1455–60.PubMed
112.
Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227–36.PubMed
113.
Chou S, Ercolani RJ, Derakhchan K. Antiviral activity of maribavir in combination with drugs active against human cytomegalovirus. Amntiviral Res 2018;157:128–133.
114.
Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomized trial. Lancet Infect Dis. 2011;11(4):284–92.PubMed
115.
Maertens J, Cordonnier C, Jaksch P, Poire X, Uknis M, Wu J, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019;381(12):1136–47.PubMed
116.
Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis. 2019;68(8):1255–64.PubMed
117.
Deng R, Wang Y, Maia M, Burgess T, McBride JM, Liao XC, et al. Pharmacokinetics and exposure-response analysis of RG7667, a combination of two anticytomegalovirus monoclonal antibodies, in a phase 2a randomized trial to prevent cytomegalovirus infection in high-risk kidney transplant recipients. Antimicrob Agents Chemother. 2018;62(2).
118.
119.
Barrett AJ, Bollard CM. The coming of age of adoptive T cell therapy for viral infection after stem cell transplantation. Ann Transl Med. 2015;3(5):62.PubMedPubMedCentral
120.
121.
Erard V, Guthrie KA, Seo S, Smith J, Huang M, Chien J, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 2015;61(1):31–9.PubMedPubMedCentral
122.
Shmueli E, Or R, Shapira MY, Resnick IB, Caplan O, Bdolah-Abram T, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis. 2014;209(4):557–61.PubMed
123.
Simon P, Sasse M, Laudi S, Petroff D, Bartels M, Kaisers UX, et al. Two strategies for prevention of cytomegalovirus infections after liver transplantation. World J Gastroenterol. 2016;22(12):3412–7.PubMedPubMedCentral
124.
Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation. 2012;93(1):61–8.PubMed
125.
Bodro M, Sabe N, Llado L, Baliellas C, Niubo J, Castellote J, et al. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transpl. 2012;18(9):1093–9.PubMed
126.
Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8(1):69–77.PubMed
127.
Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6(9):2134–43.PubMed
128.
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33(9):e13512.
129.
Jaamei N, Koutsokera A, Pasquier J, Mombelli M, Meylan P, Pascual M, et al. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients. Transpl Infect Dis. 2018;20(4):e12893.PubMed
130.
Kabbani D, Hirji A, Hernandez C, Malhi H, Mabilangan C, Chandrarathne S, et al. High incidence of clinically significant cytomegalovirus infection in CMV D+/R+ lung transplant recipients receiving 3 months of antiviral prophylaxis. Transpl Infect Dis. 2019;21(4):e13094.PubMed
131.
Schoeppler KE, Lyu DM, Grazia TJ, Crossno JT Jr, Vandervest KM, Zamora MR. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant. 2013;13(2):376–82.PubMed
132.
Johansson I, Martensson G, Nystrom U, Nasic S, Andersson R. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients. BMC Infect Dis. 2013;13:582.PubMedPubMedCentral
133.
Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis. 2012;14(3):248–58.PubMed
134.
Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor T, Grazia T, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004;4(10):1635–42.PubMed
135.
Hecker M, Hecker A, Askevold I, Kuhnert S, Reichert M, Guth S, et al. Indefinite cytomegalovirus prophylaxis with valganciclovir after lung transplantation. Transpl Infect Dis. 2019;21(5):e13138.PubMed
136.
Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9(5):1205–13.PubMed
137.
Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4(4):611–20.PubMed
138.
Fisher CE, Knudsen JL, Lease ED, Jerome KR, Rakita RM, Boeckh M, et al. Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients. Clin Infect Dis. 2017;65(1):57–63.PubMedPubMedCentral
139.
Padulles A, Colom H, Bestard O, Melilli E, Sabe N, Rigo R, et al. Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients. Antimicrob Agents Chemother. 2016;60(4):1992–2002.PubMedPubMedCentral
140.
Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther. 2009;14(5):697–704.PubMed
141.
Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A. 2000;97(14):8039–44.PubMedPubMedCentral
142.
Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation. 2011;92(2):217–23.PubMed
143.
Couzi L, Helou S, Bachelet T, Moreau K, Martin S, Morel D, et al. High incidence of anticytomegalovirus drug resistance among D + R- kidney transplant recipients receiving preemptive therapy. Am J Transplant. 2012;12(1):202–9.PubMed
144.
Sahoo MK, Lefterova MI, Yamamoto F, Waggoner JJ, Chou S, Holmes SP, et al. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol. 2013;51(11):3700–10.PubMedPubMedCentral
145.
Garrigue I, Moulinas R, Recordon-Pinson P, Delacour ML, Essig M, Kaminski H, et al. Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients. J Clin Virol. 2016;80:74–81.PubMed
146.
Houldcroft CJ, Bryant JM, Depledge DP, Margetts BK, Simmonds J, Nicolaou S, et al. Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus. Front Microbiol. 2016;7:1317.PubMedPubMedCentral
147.
Bonatti H, Sifri CD, Larcher C, Schneeberger S, Kotton C, Geltner C. Use of cidofovir for cytomegalovirus disease refractory to ganciclovir in solid organ recipients. Surg Infect. 2017;18(2):128–36.
148.
Patel SJ, Kuten SA, Knight RJ, Hong DM, Gaber AO. Resolution of mild ganciclovir-resistant cytomegalovirus disease with reduced-dose cidofovir and CMV-hyperimmune globulin. J Transp Secur. 2014;2014:342319.
149.
Ravens S, Schultze-Florey C, Raha S, Sandrock I, Drenker M, Oberdorfer L, et al. Human gammadelta T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. Nat Immunol. 2017;18(4):393–401.PubMed
150.
Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11(5):1079–84.PubMed
151.
Macesic N, Langsford D, Nicholls K, Hughes P, Gottlieb DJ, Clancy L, et al. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient. Am J Transplant. 2015;15(3):827–32.PubMed
152.
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.PubMedPubMedCentral
153.
Morita S, Shinoda K, Tamaki S, Kono H, Asanuma H, Nakagawa K, et al. Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: a case report and literature review. J Clin Virol. 2016;82:133–8.PubMed
154.
Chon WJ, Kadambi PV, Xu C, Becker YT, Witkowski P, Pursell K, et al. Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago. Case Rep Nephrol Dial. 2015;5(1):96–105.PubMedPubMedCentral
155.
Germi R, Mariette C, Alain S, Lupo J, Thiebaut A, Brion JP, et al. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antivir Res. 2014;101:57–61.PubMed
156.
Verkaik NJ, Hoek RA, van Bergeijk H, van Hal PT, Schipper ME, Pas SD, et al. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature. Transpl Infect Dis. 2013;15(6):E243–9.PubMed
157.
Avery RK, Mossad SB, Poggio E, Lard M, Budev M, Bolwell B, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010;90(4):419–26.PubMed
158.
Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008;46(9):1455–7.PubMed
Metadaten
Titel
Human Cytomegalovirus Prophylaxis and Treatment in Lung Transplantation in the Current Era
verfasst von
Kathleen M. Mullane
Publikationsdatum
22.02.2020
Verlag
Springer US
Erschienen in
Current Pulmonology Reports / Ausgabe 1/2020
Elektronische ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-020-00246-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise